Two vs. three drugs: which works better for slowing prostate cancer?

This study aimed to find out if adding a chemotherapy drug (docetaxel) to a standard two-drug hormone therapy regimen works better for controlling prostate cancer that has spread but is still limited in volume. Men with this specific type of cancer would have been randomly assigned to receive either the two-drug or three-drug combination. The main goal was to see which treatment kept the cancer from growing longer. The study was withdrawn before any participants were enrolled.